A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Insulin is a hormone which is produced by the human pancreas for the lowering of blood sugar.
In patients who don't produce enough insulin, additional insulin must be given several times
per day by injections. Nastech Pharmaceutical Company Inc. has developed a new insulin nasal
spray, as a possible way to improve patient compliance with intensive insulin treatment
plans. This study is being conducted to see how Nastech's insulin nasal spray affects
post-meal glucose levels compared with rapid acting insulin (i.e., insulin aspart) in Type 2
diabetics who are already taking oral antidiabetic medications and/or insulin therapy.
Insulin aspart is marketed as NovoLog® in the United States. The safety of insulin nasal
spray and how well it is tolerated as compared to NovoLog will also be evaluated.